Peringatan Keamanan

The poor safety profile of necitumumab has been one of the major limitations of its use. Rigorous monitoring of the following adverse events is recommended for the use of this drug: cardiopulmonary arrest, hypomagnesia, venous and arterial thromboembolic events, dermatologic toxicities, and infusion-related reactions. Due to observations of increased toxicity and mortality in treatment of non-squamous NSCLC, necitumumab is only recommended for the treatment of squamous NSCLC in combination with cisplatin and gemcitabine. Animal studies suggest potential embryo-fetal toxicity.

Necitumumab

DB09559

biotech approved investigational

Deskripsi

Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression. Binding of necitumumab to EGFR induces receptor internalization and degradation, thereby preventing further activation of EGFR which is beneficial in NSCLC as many patients have increased protein expression of EGFR. Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC).

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Elimination half life is approximately 14 days.
Volume Distribusi Steady state volume of distribution is 7.0 L.
Klirens (Clearance) 14.1 mL/h

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

411 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Necitumumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Necitumumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Necitumumab.
Estrone Estrone may increase the thrombogenic activities of Necitumumab.
Estradiol Estradiol may increase the thrombogenic activities of Necitumumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Necitumumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Necitumumab.
Mestranol Mestranol may increase the thrombogenic activities of Necitumumab.
Estriol Estriol may increase the thrombogenic activities of Necitumumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Necitumumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Necitumumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Necitumumab.
Tibolone Tibolone may increase the thrombogenic activities of Necitumumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Necitumumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Necitumumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Necitumumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Necitumumab.
Zeranol Zeranol may increase the thrombogenic activities of Necitumumab.
Equol Equol may increase the thrombogenic activities of Necitumumab.
Promestriene Promestriene may increase the thrombogenic activities of Necitumumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Necitumumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Necitumumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Necitumumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Necitumumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Necitumumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Necitumumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Necitumumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Necitumumab.
Formononetin Formononetin may increase the thrombogenic activities of Necitumumab.
Estetrol Estetrol may increase the thrombogenic activities of Necitumumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Necitumumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Necitumumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Necitumumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Necitumumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Necitumumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Necitumumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Necitumumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Necitumumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Necitumumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Necitumumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Necitumumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Necitumumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Necitumumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Necitumumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Necitumumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Necitumumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Necitumumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Necitumumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Necitumumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Necitumumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Necitumumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Necitumumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Necitumumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Necitumumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Necitumumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Necitumumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Necitumumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Necitumumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Necitumumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Necitumumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Necitumumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Necitumumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Necitumumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Necitumumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Necitumumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Necitumumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Necitumumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Necitumumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Necitumumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Necitumumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Necitumumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Necitumumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Necitumumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Necitumumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Necitumumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Necitumumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Necitumumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Necitumumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Necitumumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Necitumumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Necitumumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Necitumumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Necitumumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Necitumumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Necitumumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Necitumumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Necitumumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Necitumumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Necitumumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Necitumumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Necitumumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Necitumumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Necitumumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Necitumumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Necitumumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Necitumumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Necitumumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Necitumumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Necitumumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Necitumumab.

Target Protein

Epidermal growth factor receptor EGFR

Referensi & Sumber

Artikel (PubMed)
  • PMID: 15757893
    Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D, Kang X, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Zhu Z: A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem. 2005 May 20;280(20):19665-72. Epub 2005 Mar 9.
  • PMID: 20197484
    Kuenen B, Witteveen PO, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F, Katz T, Youssoufian H, Zhu J, Rowinsky EK, Voest EE: A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res. 2010 Mar 15;16(6):1915-23. doi: 10.1158/1078-0432.CCR-09-2425. Epub 2010 Mar 2.
  • PMID: 26729188
    Garnock-Jones KP: Necitumumab: First Global Approval. Drugs. 2016 Feb;76(2):283-9. doi: 10.1007/s40265-015-0537-0.
  • PMID: 25701169
    Zhou F, Zhou C: Necitumumab for patients with non-squamous NSCLC: uninspiring results. Lancet Oncol. 2015 Mar;16(3):246-7. doi: 10.1016/S1470-2045(15)70059-8. Epub 2015 Feb 18.

Contoh Produk & Brand

Produk: 3 • International brands: 0
Produk
  • Portrazza
    Solution • 16 mg/1mL • Intravenous • US • Approved
  • Portrazza
    Injection, solution, concentrate • 800 mg • Intravenous • EU
  • Portrazza
    Solution • 16 mg / mL • Intravenous • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul